Healx Logo

Rare Treatment Accelerator

The Rare Treatment Accelerator programme connects academic groups, patient groups and early-stage biotechs with Healx to unlock the power of repurposed drugs for rare diseases. Working together, we can quickly turn your research, insights and promising repurposing assets into treatments that will benefit rare disease patients.

Unlock the power of repurposed drugs

Through our Rare Treatment Accelerator (RTA) programme, we partner with academic groups, patient organisations and early-stage biotechs who have identified promising drug repurposing opportunities for rare diseases but who need additional financial and clinical resources to take these all the way to patients.

By applying our AI technology, drug development and clinical expertise, along with the necessary financial resources, we will evaluate, enhance and accelerate the development of your repurposed drugs – with the aim of starting a clinical trial within 6-12 months from project start.

We’re particularly keen to hear about projects where there is good evidence that the repurposed drug has therapeutic effects in preclinical disease models and is suitable to move towards human clinical trials.

And whilst we’re very interested in diseases that fit with our current portfolio, we also welcome applications from groups working on other rare conditions where relevant assets, resources and data are available to allow us to fast-track projects to the clinic.

Apply here
Icon

How Healx progress drug repurposing opportunities

Speed

Speed

By applying our in-house expertise and technology to your drug repurposing project we’re able to quickly plan and initiate clinical trials - within 6-12 months

Funding

Funding

We will manage the costs of clinical trials and regulatory approval for all selected drug repurposing opportunities

Expertise

Expertise

The expertise of our AI, drug development and commercial teams helps us evaluate, enhance and accelerate the development of your repurposed drugs

Applying to the RTA

Interested in partnering with us? The first step is to complete this short eligibility questionnaire which will help us learn more about your work and disease area(s) of interest.

We will review every questionnaire and contact each group individually to offer feedback. Where you have the necessary elements for your drug development programme to reach the clinic, we’ll invite you to complete a full application.

In terms of our collaborative approach, we are primarily looking to in-license promising therapies, but are also open to other models of collaboration, such as co-development of the technology through co-investing.

Please take a look at the FAQs below for more info on entry criteria and the selection process. For all other questions, please email our team at accelerate@healx.io

And if you’re interested in the RTA programme but aren’t ready to apply right now you can stay up-to-date with the latest programme updates by registering your interest here.

The RTA programme is open for entries all year round – we look forward to receiving your application form soon. Good luck!

Apply here
Icon

Assessment process

Icon

Partnerships

Icon FAQs

The Rare Treatment Accelerator 2.0 is Healx’s partnering programme for academic groups, patient groups and early-stage biotechs with promising drug repurposing opportunities for rare diseases. Working together with selected applicants, Healx will leverage its AI, drug discovery and clinical expertise to accelerate novel therapies towards clinical trials in a typical timeframe of 6-12 months.

The RTA programme gives participants access to Healx, a partner that is well-funded and has the AI, drug discovery and clinical expertise needed to translate research into reality – accelerating novel treatments and drug repurposing assets through clinical trials and towards patients.

The Rare Treatment Accelerator (RTA) 2.0 is open to all academic, patient and early-stage biotech groups that have a promising drug repurposing opportunity for a rare disease. Although different regions have their own definitions of a rare disease, Healx broadly defines it as any condition that affects less than 1 person in 2,000 (5 in 10,000).

Healx are very interested in groups focused on rare diseases that complement Healx’s existing expertise and portfolio, but Healx would always be open to other diseases where applicants have the information and assets that can best take advantage of Healx’s drug discovery and development expertise.

The term promising means that there is a good preclinical hypothesis and evidence that the drug repurposing asset works in preclinical models of the rare disease(s), and is therefore suitable to move to a human clinical trial.

We are ideally looking for promising drug repurposing assets for a rare disease with a strong preclinical package of data from validated models of the disease. The term promising means that there is a good preclinical hypothesis and evidence that the drug repurposing asset works in preclinical models of the rare disease(s), and is therefore suitable to move to a human clinical trial. These diseases should also have validated clinical endpoints/outcome measures to enable translation to trials as well as sufficient numbers of patients to enable clinical trial and commercial feasibility. We would also be looking for IP protection, or the opportunity for it, as well as good off-label use protection.

Whilst the Rare Treatment Accelerator 2.0 is focused on accelerating promising repurposed drugs to clinical trials, we are still very interested in hearing from patient groups who want to work with us. Please fill in this form so the team can learn more about your work and disease area of interest or reach out to accelerate@healx.io

Whilst the Rare Treatment Accelerator 2.0 is focused on in-licensing promising repurposed therapies for rare diseases that have been identified by patient groups, academic groups or early-stage biotechs, we are flexible and would be open to other models of collaboration, such as co-development of the technology through co-investing. To discuss this further please reach out to partnerships@healx.io or visit our Partnerships page.

Interested groups for the Rare Treatment Accelerator 2.0 can apply here.

There is no closing date for this Rare Treatment Accelerator 2.0. You can apply whenever you feel ready, starting with the eligibility questionnaire.

There is no cost to apply, and the collaboration to progress a clinic-ready asset for a particular disease will be at no cost to successful applicants.

For this stage of the application, Healx asks groups to submit only non-confidential data. If  an application progresses to further review and due diligence, appropriate confidentiality agreements will be put in place if Healx needs to evaluate confidential data as part of this process.

The Rare Treatment Accelerator panel is made up of Healx’s senior leadership team (including our Chief Medical Officer, Chief Scientific Officer and Chief Collaboration Officer) and members of our commercial, preclinical and clinical teams, who collectively hold over 100 years of drug discovery expertise in industry and not-for-profit organisations.

If you have any questions, you can always reach out to our team at accelerate@healx.io

Our technology

Our AI leverages its unique combination of algorithms to predict and de-risk novel connections in biomedical data, and move the most promising ones towards the clinic.

About Healx

We’re a next-generation team of drug hunters, AI engineers and bioinformaticians, all working together to accelerate the discovery of new treatments for rare diseases.